Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 7/20 | 0.54 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.43 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.43 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | HRH1 | P35367 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 3/20 | 0.39 |
| ▸ | RAD52 | P43351 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13762258 | 0.98 | HRH3 (0.50) | HRH3CARM1PRMT6PRMT8SIGMAR1 | |
| SCHEMBL12257623 | 0.94 | HRH3 (0.50) | HRH3CARM1PRMT6PRMT8SIGMAR1 | |
| SCHEMBL10259141 | 0.92 | CARM1 (0.46) | HRH3CARM1PRMT6PRMT8SIGMAR1 | |
| SCHEMBL12257608 | 0.88 | CARM1 (0.41) | HRH3CARM1PRMT6PRMT8SIGMAR1 | |
| SCHEMBL13137785 | 0.85 | CARM1 (0.54) | HRH3CARM1PRMT6PRMT8SIGMAR1 | |
| SCHEMBL7745180 | 0.85 | CARM1 (0.54) | HRH3CARM1PRMT6PRMT8SIGMAR1 | |
| SCHEMBL10192177 | 0.83 | CARM1 (0.56) | HRH3CARM1PRMT6PRMT8SIGMAR1 | |
| SCHEMBL13884244 | 0.83 | SMN1; SMN2 (0.41) | CARM1PRMT6PRMT8ALDH1A1MAPT | |
| SCHEMBL24621746 | 0.79 | DRD2 (0.35) | HRH3ALDH1A1MAPTMAPK1SMN1; SMN2 | |
| SCHEMBL24621739 | 0.79 | DRD2 (0.35) | HRH3ALDH1A1MAPTMAPK1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100222319-A1 | NICOTINAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2010-09-02 | — | — | US | disclosed |
| WO-2009074749-A2 | NICOTINAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2009-06-18 | — | — | WO | disclosed |
| US-7153861-B2 | For therapy of atheroscelerosis | SMITHKLINE BEECHAM P.L.C. (GB) | 2006-12-26 | — | — | US | disclosed |
| US-20040097525-A1 | For therapy of atheroscelerosis | SMITHKLINE BEECHAM PLC | 2004-05-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040097525-A1 | For therapy of atheroscelerosis | LYPLA2, LOXL2, LYPLA1 | HRH3 3940/4885CARM1 4752/4885PRMT6 3439/4885 |
| US-20100222319-A1 | NICOTINAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | NNT, NAMPT, NQO1 | HRH3 1334/4885CARM1 762/4885PRMT6 748/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.